BresaGen is a biotechnology company committed to the commercial development of protein and peptide therapeutics.
Drawing on two decades of experience, the company has earned a reputation for excellence in the process development and manufacture of recombinant protein and peptide pharmaceuticals.

BresaGen is based in Adelaide, South Australia and operates a cGMP facility with the capacity to manufacture recombinant proteins and peptides. The Company has human therapeutic API candidates and offers contract process development and manufacturing services. BresaGen has commercialised its first product, EquiGen™, a horse growth hormone, and executed its first contract for supply of human growth hormone API. It's latest venture is protEcol Services, a contract service business unit within BresaGen Limited offering process development and manufacture of recombinant peptides and proteins.